Universal RSV ‘immunisation’ on the horizon for infants
A monoclonal antibody to protect all babies against respiratory syncytial virus could be approved overseas within months, with Australia likely to follow, say infectious diseases specialists.
Trials of the agent, nirsevimab, shows a single IM injection effectively immunises infants against respiratory syncytial virus (RSV), which is one of the leading causes of hospitalisation for bronchiolitis and pneumonia.